These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 33968710)

  • 1. Circulating Biomarkers for Early Stage Non-Small Cell Lung Carcinoma Detection: Supplementation to Low-Dose Computed Tomography.
    Kan CFK; Unis GD; Li LZ; Gunn S; Li L; Soyer HP; Stark MS
    Front Oncol; 2021; 11():555331. PubMed ID: 33968710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liquid biopsy for lung cancer early detection.
    Santarpia M; Liguori A; D'Aveni A; Karachaliou N; Gonzalez-Cao M; Daffinà MG; Lazzari C; Altavilla G; Rosell R
    J Thorac Dis; 2018 Apr; 10(Suppl 7):S882-S897. PubMed ID: 29780635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miRNAs as biomarkers and for the early detection of non-small cell lung cancer (NSCLC).
    Han Y; Li H
    J Thorac Dis; 2018 May; 10(5):3119-3131. PubMed ID: 29997981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-based liquid biopsy: Insights into early detection and clinical management of lung cancer.
    Liu C; Xiang X; Han S; Lim HY; Li L; Zhang X; Ma Z; Yang L; Guo S; Soo R; Ren B; Wang L; Goh BC
    Cancer Lett; 2022 Jan; 524():91-102. PubMed ID: 34656690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Lung cancer screening in high-risk subjects: early detection with LDCT and risk stratification using miRNA-based blood test].
    Sestini S; Boeri M; Marchianò A; Silva M; Calareso G; Galeone C; Sozzi G; Pastorino U
    Epidemiol Prev; 2016; 40(1 Suppl 1):42-50. PubMed ID: 26951732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
    Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
    Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening.
    Sestini S; Boeri M; Marchiano A; Pelosi G; Galeone C; Verri C; Suatoni P; Sverzellati N; La Vecchia C; Sozzi G; Pastorino U
    Oncotarget; 2015 Oct; 6(32):32868-77. PubMed ID: 26451608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor cell clusters are a potential biomarker for detection of non-small cell lung cancer.
    Manjunath Y; Upparahalli SV; Suvilesh KN; Avella DM; Kimchi ET; Staveley-O'Carroll KF; Li G; Kaifi JT
    Lung Cancer; 2019 Aug; 134():147-150. PubMed ID: 31319973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of direct referral for fast CT scan in early lung cancer detection in general practice. A clinical, cluster-randomised trial.
    Guldbrandt LM
    Dan Med J; 2015 Mar; 62(3):. PubMed ID: 25748876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-dose computed tomography for lung cancer screening in high-risk populations: a systematic review and economic evaluation.
    Snowsill T; Yang H; Griffin E; Long L; Varley-Campbell J; Coelho H; Robinson S; Hyde C
    Health Technol Assess; 2018 Nov; 22(69):1-276. PubMed ID: 30518460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer.
    Yang X; Zhang Q; Zhang M; Su W; Wang Z; Li Y; Zhang J; Beer DG; Yang S; Chen G
    Int J Biol Sci; 2019; 15(8):1712-1722. PubMed ID: 31360113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantum Dot Based Nano-Biosensors for Detection of Circulating Cell Free miRNAs in Lung Carcinogenesis: From Biology to Clinical Translation.
    Singh RD; Shandilya R; Bhargava A; Kumar R; Tiwari R; Chaudhury K; Srivastava RK; Goryacheva IY; Mishra PK
    Front Genet; 2018; 9():616. PubMed ID: 30574163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.
    Bracht JWP; Mayo-de-Las-Casas C; Berenguer J; Karachaliou N; Rosell R
    Curr Oncol Rep; 2018 Jul; 20(9):70. PubMed ID: 30030656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. miRNA and cancer; computational and experimental approaches.
    Tutar Y
    Curr Pharm Biotechnol; 2014; 15(5):429. PubMed ID: 25189575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating microRNA-590-5p functions as a liquid biopsy marker in non-small cell lung cancer.
    Khandelwal A; Seam RK; Gupta M; Rana MK; Prakash H; Vasquez KM; Jain A
    Cancer Sci; 2020 Mar; 111(3):826-839. PubMed ID: 31520555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-based biomarkers for diagnosis of non-small cell lung cancer (NSCLC).
    Liao J; Shen J; Leng Q; Qin M; Zhan M; Jiang F
    Thorac Cancer; 2020 Mar; 11(3):762-768. PubMed ID: 31994346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers in Lung Cancer Screening: a Narrative Review.
    Marmor HN; Zorn JT; Deppen SA; Massion PP; Grogan EL
    Curr Chall Thorac Surg; 2023 Feb; 5():. PubMed ID: 37016707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA).
    Lim M; Kim CJ; Sunkara V; Kim MH; Cho YK
    Micromachines (Basel); 2018 Feb; 9(3):. PubMed ID: 30424034
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.